The trial achieved equally its Key endpoints, with semaglutide two.four mg demonstrating statistically sizeable and excellent improvements in liver fibrosis with no worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in individuals with MASH when compared with placebo.oneThe following si